- Supported exchanges /
- NASDAQ /
- BPTSY.NASDAQ
Biophytis S.A. (BPTSY NASDAQ) stock market data APIs
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Biophytis S.A. Financial Data Overview
2.86 | |
2.86 | |
- | |
2.86 | |
2.86 | |
2.82-39.2 | |
1 558 K | |
287 K | |
0 | |
1.172 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Biophytis S.A. Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -13 804 000
- Earnings Per Share -132.13
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Biophytis S.A. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Biophytis S.A. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: